Ambience Healthcare vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ambience Healthcare raised $370M (~$1B valuation) and hit $30M ARR with ambient AI documentation across 100+ specialties, eliminating the documentation burden driving clinician burnout.
About
Ambience Healthcare was founded in 2020 in San Francisco with a mission to eliminate the documentation burden that drives clinician burnout and degrades patient care quality across health systems. The company builds ambient AI documentation technology that listens to clinical encounters across more than 100 medical and surgical specialties, generating accurate, complete clinical notes in the background without requiring clinicians to dictate or type. Ambience's core technology leverages large language models purpose-trained on clinical language, specialty-specific note structures, and electronic health record formatting requirements to produce documentation that is ready for review with minimal editing.\n\nAmbience's platform is deployed across health systems ranging from large academic medical centers to independent practices, covering more than 100 specialties including primary care, surgery, oncology, behavioral health, and pediatrics. Unlike narrower documentation tools that focus on a single specialty or encounter type, Ambience's breadth allows health systems to deploy a single solution enterprise-wide. The platform integrates with major EHR systems including Epic and Cerner, embedding documentation into existing clinical workflows without requiring behavior change from clinicians. Ambience achieved approximately $30 million in annual recurring revenue as of May 2025.\n\nAmbience Healthcare has raised approximately $370 million in total funding, approaching a $1 billion valuation, from investors including Andreessen Horowitz and other leading healthcare-focused venture firms. The company competes with Nuance DAX, Suki, and Nabla in the ambient documentation space but differentiates through its specialty breadth, enterprise EHR integration depth, and strong health system relationships. As health systems face escalating clinician burnout and documentation-driven inefficiency, Ambience's full-enterprise approach positions it as a platform of record for ambient clinical intelligence.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.